title: Paraneoplastic antibody during follow-up of a patient with anti-Ri-associated paraneoplastic neurological syndrome.
abstract: BACKGROUND
  The role of classical antineuronal antibody determinations to confirm the paraneoplastic aetiology of a neurological syndrome is well established. However, the value of antineuronal antibody estimation during follow-up of paraneoplastic neurological syndromes (PNS) is not known.
  
  
  OBJECTIVE
  Prospective analysis of antibody concentrations in follow-up serum samples from a patient with anti-Ri-associated PNS.
  
  
  METHODS
  Semiquantitative estimation of antibody concentrations with an ELISA using recombinant Ri antigen.
  
  
  RESULTS
  Semiquantitative estimation of circulating anti-Ri antibodies demonstrated a renewed increase in antibody levels preceding relapse of the cancer, as confirmed using F-fluorodeoxyglucose positron emission tomography (FDG-PET).
  
  
  CONCLUSIONS
  This is the first prospective report on serial anti-Ri antibody determinations. As a large increase in antineuronal antibody concentrations in follow-up serum samples preceded relapse of the cancer, paraneoplastic antineuronal antibodies may represent a marker for tumour activity in this case. These results warrant further multicentre studies to investigate the ability of serial quantification of classical antineuronal antibodies in monitoring PNS and in predicting relapse of cancers.
authors.affiliation: Neurologische Klinik und Poliklinik der Albert-Ludwigs-Universitaet Freiburg, Breisacher Strasse 64, Freiburg, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Stich
authors.forename: C
authors.initials: C
authors.lastname: Rasiah
authors.forename: S
authors.initials: S
authors.lastname: Rauer
mesh_terms: D000906:Antibodies / Q000032:analysis* / Q000097:blood; D000951:Antigens, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D001943:Breast Neoplasms / Q000276:immunology / Q000503:physiopathology; D002277:Carcinoma / Q000276:immunology / Q000503:physiopathology; D002526:Cerebellar Diseases / Q000276:immunology / Q000503:physiopathology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008482:Mediastinum / Q000000981:diagnostic imaging / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000276:immunology*; D009419:Nerve Tissue Proteins / Q000276:immunology*; D000090682:Neuro-Oncological Ventral Antigen; D020361:Paraneoplastic Syndromes, Nervous System / Q000097:blood / Q000175:diagnosis* / Q000276:immunology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016601:RNA-Binding Proteins / Q000276:immunology*; D011877:Radionuclide Imaging; D015854:Up-Regulation / Q000276:immunology
chemical_list: D000906:Antibodies; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009419:Nerve Tissue Proteins; D000090682:Neuro-Oncological Ventral Antigen; D016601:RNA-Binding Proteins